Ablative Solutions Banks $77 Million in Series D Funding for Unique Approach to Treating Uncontrolled Hypertension

Ablative Solutions, Inc. announced on 1/3/19 the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor. Existing investors including Michigan Accelerator Fund, Novus Biotechnology and other individual investors also participated the Series D funding round.